Becton, Dickinson and Company (BDX) Q1 2026 Earnings
Becton, Dickinson and Company reported Q1 2026 revenue of $4.7B (-10.6% YoY), beat analyst consensus of $4.7B by $42.2M. Diluted EPS came in at $2.90 (-13.4% YoY), beat the $2.78 consensus by $0.12. Becton, Dickinson and Company reports across 3 business segments, led by Medical, Life Sciences, and Interventional.
Financial Snapshot
Trailing eight quarters through Q1 2026
Q1 2026 Earnings FAQ
Common questions about Becton, Dickinson and Company's Q1 2026 earnings report.
Becton, Dickinson and Company (BDX) reported Q1 2026 earnings on May 7, 2026 before market open.
Becton, Dickinson and Company reported revenue of $4.7B and diluted EPS of $2.90 for Q1 2026.
Revenue beat the consensus estimate of $4.7B by $42.2M. EPS beat the consensus estimate of $2.78 by $0.12.
Compared to the same quarter a year prior, revenue declined 10.6% from $5.3B a year earlier and diluted EPS declined 13.4% from $3.35.
You can read the 8-K earnings release (0001628280-26-031638) and the 10-Q periodic report (0000010795-26-000026) directly on SEC EDGAR. The filing index links above go to sec.gov.